Vernal Keratoconjunctivitis

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 321 Experts worldwide ranked by ideXlab platform

William Power - One of the best experts on this subject based on the ideXlab platform.

Alessandro Lambiase - One of the best experts on this subject based on the ideXlab platform.

  • Current and emerging treatment options for Vernal Keratoconjunctivitis
    Expert Opinion on Orphan Drugs, 2017
    Co-Authors: Marta Sacchetti, Stefano Bonini, Marcella Nebbioso, Alice Bruscolini, Irene Abicca, Maurizio La Cava, Alessandro Lambiase
    Abstract:

    Introduction: Vernal Keratoconjunctivitis (VKC) is a rare, chronic allergic disease affecting children in prepuberal age. The hallmark of VKC is the presence of conjunctival upper tarsal and/or lim...

  • Prospective, multicenter demographic and epidemiological study on Vernal Keratoconjunctivitis: a glimpse of ocular surface in Italian population.
    Ophthalmic epidemiology, 2009
    Co-Authors: Alessandro Lambiase, Andrea Leonardi, S. Minchiotti, A.g. Secchi, Maurizio Rolando, Giovanni Calabria, Jelka G. Orsoni, Enrica Zola, Giuseppe Ferreri, Pasquale Aragona
    Abstract:

    Purpose: To evaluate the frequency and epidemiological features of Vernal Keratoconjunctivitis (VKC) in Italy. Methods: a specific electronic clinical chart for Vernal Keratoconjunctivitis was created to standardize: 1) medical history; 2) diagnostic criteria; 3) signs and symptoms; and 4) treatments. This study involved 6 Italian referral centers for ocular surface diseases: between March 2005 and March 2006, all referred patients were included, clinical data collected and statistically examined. Results: The mean age of the Vernal Keratoconjunctivitis population (n = 156) was 13.8 ± 8.8 with 64.1% of subjects under 14 years of age and a male/female ratio of 3.5:1. Among VKC patients, 48.7% showed associated systemic allergic diseases. Only 32.1% of patients were positive for RAST and/or prick test. The limbal form (53.8%) was the most frequent subtype of Vernal Keratoconjunctivitis. Approximately 9% of patients showed a severe form of Vernal Keratoconjunctivitis. At the first visit patients were treated...

  • Preliminary evidence of the efficacy of probiotic eye-drop treatment in patients with Vernal Keratoconjunctivitis
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2007
    Co-Authors: Alfonso Iovieno, Marta Sacchetti, Alessandro Lambiase, Alessandra Micera, B. Stampachiacchiere, Stefano Bonini
    Abstract:

    Background Probiotics have been shown to improve allergic inflammation. The aim of this study was to evaluate the efficacy of Lactobacillus Acidophilus eye-drops in controlling signs and symptoms of Vernal Keratoconjunctivitis (VKC).

  • Clinical grading of Vernal Keratoconjunctivitis.
    Current Opinion in Allergy and Clinical Immunology, 2007
    Co-Authors: Stefano Bonini, Marta Sacchetti, Flavio Mantelli, Alessandro Lambiase
    Abstract:

    Purpose of reviewThe purpose of the present review is to provide an overview on the clinical features of Vernal Keratoconjunctivitis on the basis of cases series presented in the literature. Furthermore, a new grading system of Vernal Keratoconjunctivitis based on the severity of the disease is prop

  • Montelukast, a Leukotriene Receptor Antagonist, in Vernal Keratoconjunctivitis Associated With Asthma
    Archives of ophthalmology (Chicago Ill. : 1960), 2003
    Co-Authors: Alessandro Lambiase, Stefano Bonini, Alice Bruscolini, Guido Rasi, M. Coassin, Sergio Bonini
    Abstract:

    Methods: Twelve patients with Vernal Keratoconjunctivitis and asthma were enrolled in this pilot study. Topical eyedrops or any systemic treatment was discontinued for at least 7 days before montelukast treatment. Patients were asked to grade their ocular discomfort daily. The following signs and symptoms were also recorded and graded through medical examination at baseline, after 15 days of treatment, and 15 days after treatment discontinuation: physician-evaluated tarsal and bulbar papillae, hyperemia, secretion, and chemosis; and patientevaluated itching, burning, tearing, photophobia, foreign body sensation, secretion, and redness. Peak expiratory flow rate at 8 AM was also recorded. Samples were collected at the same time points for enzyme-linked immunosorbent assay measurement of leukotriene B4 in tears and leukotriene E4 in urine. Results: Eight of the 10 patients evaluated reported a reduction in symptoms at the end of treatment. Montelukast treatment significantly decreased physicianrated hyperemia, secretion, and chemosis as well as patient-rated burning, tearing, photophobia, secretion, and redness. Effects persisted 15 days after discontinuation of treatment. Clinical changes were associated with a significant increase in leukotriene B4 in tears and a significant decrease in leukotriene E4 in urine after 15 days of treatment. Conclusion: The significant and persistent reduction of ocular signs and symptoms in asthmatic patients with Vernal Keratoconjunctivitis treated for 15 days with montelukast strongly suggests the need for double-masked placebo-controlled trials to confirm the potential of this new treatment in Vernal Keratoconjunctivitis.

Todd P. Margolis - One of the best experts on this subject based on the ideXlab platform.

  • Supratarsal injection of corticosteroid in the treatment of refractory Vernal Keratoconjunctivitis.
    American journal of ophthalmology, 1996
    Co-Authors: Douglas S. Holsclaw, John P. Whitcher, Ira G. Wong, Todd P. Margolis
    Abstract:

    Purpose We studied supratarsal injection of corticosteroid as a new therapeutic modality for treating severe Vernal Keratoconjunctivitis to determine its efficacy in treating patients refractory to all conventional therapy. Methods Twelve patients with Vernal Keratoconjunctivitis resistant to all established therapy were prospectively studied by randomly assigning them to receive supratarsal injection of either short- or intermediate-acting corticosteroid. Relief of symptoms and resolution of clinical signs were evaluated. Patients were followed up to four years to identify side effects. Results All patients experienced dramatic symptomatic relief within one to five days, regardless of the type of corticosteroid injected. Marked decrease in cobblestone papillae was noted in 14.9 days (mean) after short-acting corticosteroid injection and 12.8 days after intermediate-acting corticosteroid injection (P = .65). Shield ulcers and limbal involvement resolved in one to three weeks, independent of the corticosteroid used (P = .90). No complications were observed with supratarsal injection of short-acting corticosteroid. One patient developed persistent increase of intraocular pressure after injection of intermediate-acting corticosteroid. Conclusions The dramatic symptomatic and clinical improvement suggests that supratarsal injection of corticosteroid may be a valuable therapeutic approach to treating refractory Vernal Keratoconjunctivitis. Short-acting and intermediate-acting corticosteroids were equally efficacious. Because of the lack of intraocular pressure increase observed with short-acting corticosteroid, we favor its use in supratarsal injection.

Stefano Bonini - One of the best experts on this subject based on the ideXlab platform.

  • Current and emerging treatment options for Vernal Keratoconjunctivitis
    Expert Opinion on Orphan Drugs, 2017
    Co-Authors: Marta Sacchetti, Stefano Bonini, Marcella Nebbioso, Alice Bruscolini, Irene Abicca, Maurizio La Cava, Alessandro Lambiase
    Abstract:

    Introduction: Vernal Keratoconjunctivitis (VKC) is a rare, chronic allergic disease affecting children in prepuberal age. The hallmark of VKC is the presence of conjunctival upper tarsal and/or lim...

  • Preliminary evidence of the efficacy of probiotic eye-drop treatment in patients with Vernal Keratoconjunctivitis
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2007
    Co-Authors: Alfonso Iovieno, Marta Sacchetti, Alessandro Lambiase, Alessandra Micera, B. Stampachiacchiere, Stefano Bonini
    Abstract:

    Background Probiotics have been shown to improve allergic inflammation. The aim of this study was to evaluate the efficacy of Lactobacillus Acidophilus eye-drops in controlling signs and symptoms of Vernal Keratoconjunctivitis (VKC).

  • Clinical grading of Vernal Keratoconjunctivitis.
    Current Opinion in Allergy and Clinical Immunology, 2007
    Co-Authors: Stefano Bonini, Marta Sacchetti, Flavio Mantelli, Alessandro Lambiase
    Abstract:

    Purpose of reviewThe purpose of the present review is to provide an overview on the clinical features of Vernal Keratoconjunctivitis on the basis of cases series presented in the literature. Furthermore, a new grading system of Vernal Keratoconjunctivitis based on the severity of the disease is prop

  • Montelukast, a Leukotriene Receptor Antagonist, in Vernal Keratoconjunctivitis Associated With Asthma
    Archives of ophthalmology (Chicago Ill. : 1960), 2003
    Co-Authors: Alessandro Lambiase, Stefano Bonini, Alice Bruscolini, Guido Rasi, M. Coassin, Sergio Bonini
    Abstract:

    Methods: Twelve patients with Vernal Keratoconjunctivitis and asthma were enrolled in this pilot study. Topical eyedrops or any systemic treatment was discontinued for at least 7 days before montelukast treatment. Patients were asked to grade their ocular discomfort daily. The following signs and symptoms were also recorded and graded through medical examination at baseline, after 15 days of treatment, and 15 days after treatment discontinuation: physician-evaluated tarsal and bulbar papillae, hyperemia, secretion, and chemosis; and patientevaluated itching, burning, tearing, photophobia, foreign body sensation, secretion, and redness. Peak expiratory flow rate at 8 AM was also recorded. Samples were collected at the same time points for enzyme-linked immunosorbent assay measurement of leukotriene B4 in tears and leukotriene E4 in urine. Results: Eight of the 10 patients evaluated reported a reduction in symptoms at the end of treatment. Montelukast treatment significantly decreased physicianrated hyperemia, secretion, and chemosis as well as patient-rated burning, tearing, photophobia, secretion, and redness. Effects persisted 15 days after discontinuation of treatment. Clinical changes were associated with a significant increase in leukotriene B4 in tears and a significant decrease in leukotriene E4 in urine after 15 days of treatment. Conclusion: The significant and persistent reduction of ocular signs and symptoms in asthmatic patients with Vernal Keratoconjunctivitis treated for 15 days with montelukast strongly suggests the need for double-masked placebo-controlled trials to confirm the potential of this new treatment in Vernal Keratoconjunctivitis.

  • Preservative-free diclofenac sodium 0.1% for Vernal Keratoconjunctivitis
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2003
    Co-Authors: Gennaro D'angelo, Alessandro Lambiase, R. Sgrulletta, Magdalena Cortes, Roberta Pasqualetti, Ambra Lamagna, Stefano Bonini
    Abstract:

    Purpose The aim of this study is to evaluate the efficacy of prolonged treatment with preservative-free diclofenac sodium 0.1% eye drops in patients with Vernal Keratoconjunctivitis (VKC).

Terence Joseph Mcswiney - One of the best experts on this subject based on the ideXlab platform.

Related terms

Vernal Keratoconjunctivitis - 15 days free trial to Access Experts & Abstracts